Shopping Cart
- Remove All
- Your shopping cart is currently empty
Arginyl-Glutamine TFA is a dipeptide that can reduce VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Arginyl-Glutamine TFA is a dipeptide that can reduce VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy. |
In vitro | Arginyl-Glutamine TFA (0.5-1.5 mM; 48 h) significantly reduces the expression of soluble VEGF in the medium of cultured human RPE cells in a dose-dependent manner. |
In vivo | Administering Arginyl-Glutamine TFA (1-5 g/kg/day, as a hydrochloride salt; i.p.; twice daily) significantly inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy (OIR). |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.